Literature DB >> 15964094

Attenuated hepatic inflammation and fibrosis in angiotensin type 1a receptor deficient mice.

Liu Yang1, Ramón Bataller, Jennyfer Dulyx, Thomas M Coffman, Pere Ginès, Richard A Rippe, David A Brenner.   

Abstract

BACKGROUND/AIMS: Pharmacological blockade of the renin-angiotensin system (RAS) attenuates liver fibrogenesis in rats. Here, we provide genetic evidence implicating angiotensin type 1 (AT1) receptors in liver fibrogenesis.
METHODS: Wild type (WT) and AT1a knockout [AT1a (-/-)] mice were subjected to either sham operation or bile-duct ligation. Fibrosis was assessed by Sirius Red staining and hydroxyproline hepatic content. Fibrogenic and inflammatory cytokines were measured by ELISA.
RESULTS: Bile duct ligation-induced elevation of serum liver enzymes was similar in WT and AT1a (-/-) mice. Bile duct ligated WT mice showed inflammatory changes and severe septal fibrosis. In contrast, AT1a (-/-) mice showed minor fibrotic lesions. Collagen accumulation was lower in AT1a (-/-) mice compared to WT mice. The increase in hepatic concentration of TGFbeta1 and pro-inflammatory cytokines was attenuated in AT1a (-/-) mice compared to WT mice. Immunohistochemistry analysis revealed decreased infiltration by inflammatory cells, lipid peroxidation products as well as decreased phosphorylation of c-Jun and p42/44 MAPK in AT1a (-/-) mice compared to AT1 (+/+) mice.
CONCLUSIONS: AT1 receptors play an important role in the development of fibrosis. Pharmacological blockade of AT1 receptors appears to be a promising approach to treat liver fibrosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15964094     DOI: 10.1016/j.jhep.2005.02.034

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  39 in total

Review 1.  Inflammation and fibrogenesis in steatohepatitis.

Authors:  Hideki Fujii; Norifumi Kawada
Journal:  J Gastroenterol       Date:  2012-02-07       Impact factor: 7.527

Review 2.  Anti-fibrogenic strategies and the regression of fibrosis.

Authors:  Tatiana Kisseleva; David A Brenner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2011-04       Impact factor: 3.043

Review 3.  Nonalcoholic fatty liver disease: diagnosis and relation to metabolic syndrome and approach to treatment.

Authors:  Steven D Lidofsky
Journal:  Curr Diab Rep       Date:  2008-02       Impact factor: 4.810

4.  Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD).

Authors:  Valentina Volynets; Markus A Küper; Stefan Strahl; Ina B Maier; Astrid Spruss; Sabine Wagnerberger; Alfred Königsrainer; Stephan C Bischoff; Ina Bergheim
Journal:  Dig Dis Sci       Date:  2012-03-17       Impact factor: 3.199

Review 5.  Congenital hepatic fibrosis in autosomal recessive polycystic kidney disease.

Authors:  Jessica Wen
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

6.  Linagliptin alleviates hepatic steatosis and inflammation in a mouse model of non-alcoholic steatohepatitis.

Authors:  Thomas Klein; Masato Fujii; Jan Sandel; Yuichiro Shibazaki; Kyoko Wakamatsu; Michael Mark; Hiroyuki Yoneyama
Journal:  Med Mol Morphol       Date:  2013-09-19       Impact factor: 2.309

Review 7.  Role of NADPH oxidases in liver fibrosis.

Authors:  Yong-Han Paik; Jonghwa Kim; Tomonori Aoyama; Samuele De Minicis; Ramon Bataller; David A Brenner
Journal:  Antioxid Redox Signal       Date:  2014-01-24       Impact factor: 8.401

8.  Effects of losartan on hepatic expression of nonphagocytic NADPH oxidase and fibrogenic genes in patients with chronic hepatitis C.

Authors:  Jordi Colmenero; Ramón Bataller; Pau Sancho-Bru; Marlene Domínguez; Montserrat Moreno; Xavier Forns; Miquel Bruguera; Vicente Arroyo; David A Brenner; Pere Ginès
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2009-07-23       Impact factor: 4.052

Review 9.  Renin-angiotensin system in the pathogenesis of liver fibrosis.

Authors:  Regina Maria Pereira; Robson Augusto Souza dos Santos; Filipi Leles da Costa Dias; Mauro Martins Teixeira; Ana Cristina Simões e Silva
Journal:  World J Gastroenterol       Date:  2009-06-07       Impact factor: 5.742

10.  Increased angiotensin II AT1 receptor mRNA and binding in spleen and lung of AT2 receptor gene disrupted mice.

Authors:  Jaroslav Pavel; José A Terrón; Julius Benicky; Alicia Falcón-Neri; Amita Rachakonda; Tadashi Inagami; Juan M Saavedra
Journal:  Regul Pept       Date:  2009-09-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.